Among various RNA-interference technologies, inhibition of LMP1 expression by use of an RNA-cleaving DNAzyme has been extensively explored as a potential therapeutic strategy for NPC. The gene discussed is PDLIM7; the disease is nasopharyngeal carcinoma.